Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways by analyzing live patient tumor cells. We harness these insights to develop new targeted therapies for cancer patients.
Location: United States, Minnesota, Minneapolis
Employees: 11-50
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Gravity Fu... | gravityfun... |
Mentions in press and media 13
| Date | Title | Description | Source |
| 06.03.2024 | Celcuity to Participate in Leerink Partners Global Biopharma... | - | globenewsw... |
| 07.11.2023 | Cancer research company Celcuity raises $50 million | - | bizjournal... |
| 08.05.2023 | Celcuity Inc. Schedules Release of First Quarter 2023 Financ... | MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. CELC, a clinical-stage biotechnology comp... | einpresswi... |
| 18.04.2023 | Celcuity Presents Preclinical Data on Therapeutic Effects of... | Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian an... | einpresswi... |
| 16.03.2023 | Celcuity to Present Preclinical Data on Therapeutic Effects ... | MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. CELC, a clinical-stage biotechnology c... | einpresswi... |
| 09.12.2022 | Celcuity Presents Updated Results of Phase 1b Study of Gedat... | High response rates and encouraging median progression free survival rates were observed in patients... | accesswire... |
| 09.05.2022 | Celcuity Inc. Schedules Release of First Quarter 2022 Financ... | MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechno... | accesswire... |
| 05.04.2022 | Celcuity to Participate in Upcoming Needham and Canaccord Ge... | MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotech... | accesswire... |
| 23.03.2022 | Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Fina... | Finalized pivotal Phase 3 trial design following formal meetings with FDA Received FDA Fast Track de... | accesswire... |
| 20.09.2017 | Term Sheet — Wednesday, September 20 | THE ROBOTS ARE COMING Good morning, Term Sheet readers. Paid Content Securing the enterprise without... | fortune.co... |
Show more